Home
Drugs
Bevacizumab
Clinical Trials

Clinical Trials Related to Bevacizumab

Related studies linked through entity extraction aliases.

The Phase 1b/IIa, Open-label, Dose Escalation and Dose Expansion to Evaluate Safety, Tolerability, and Preliminary Efficacy of the Combination of HCB101, Cetuximab/Bevacizumab, and FOLFOX/FOLFIRI in Advanced or Metastatic Colorectal Cancer

Status: RECRUITING
Phase: PHASE1/PHASE2

Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer

Status: RECRUITING
Phase: PHASE3

Hypofractionated Radiotherapy Combined With NALIRIF, PD-1 Antibody in Locally Recurrent Rectal Cancer(NOVELTY-R)

Status: RECRUITING
Phase: PHASE2

Radiotherapy Combined With QL1706 and Bevacizumab for Unresectable Non-metastatic Hepatocellular Carcinoma

Status: NOT_YET_RECRUITING
Phase: PHASE2

Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial

Status: RECRUITING
Phase: PHASE3

ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC

Status: RECRUITING
Phase: PHASE2

Second-line Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Fruquintinib Versus Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Bevacizumab in Metastatic Colorectal Cancer

Status: NOT_YET_RECRUITING
Phase: PHASE2

Safety and Efficacy of IB-FOLFIRI in BRAF V600E-Mutant Metastatic Colorectal Cancer

Status: RECRUITING
Phase: PHASE2

AssociatiNG Bevacizumab bEmarituzumab for GynecoLogIcal CAncer

Status: WITHDRAWN
Phase: PHASE1/PHASE2

Neoadjuvant Therapy for Locally Advanced Low Rectal Cancer (SMARTi-RC01)

Status: NOT_YET_RECRUITING
Phase: PHASE2

A Single-Arm, Multicenter, Exploratory Clinical Study of Transarterial Chemoembolization (TACE) Combined With Iparomlimab and Tuvonralimab Injection and Bevacizumab Injection for the Treatment of Unresectable, Non-Metastatic Hepatocellular Carcinoma (HCC)

Status: NOT_YET_RECRUITING
Phase: PHASE2

Combination Therapy of Senaparib and Bevacizumab for First-line Maintenance Therapy in Newly Diagnosed Advanced Homologous Recombination Proficient Ovarian Cancer Based on Exosome Protein Marker

Status: NOT_YET_RECRUITING
Phase: PHASE2

Etoposide Capsules Combined With Bevacizumab and Iparomlimab and Tuvonralimab in the Treatment of Platinum Resistant or Platinum Refractory Ovarian Cancer

Status: NOT_YET_RECRUITING
Phase: PHASE2

Paclitaxel Cationic Liposome (Hepatic Arterial Infusion) in Combination With Systemic Therapy as First-Line Treatment in Colorectal Liver Metastases

Status: RECRUITING
Phase: PHASE1

Radiotherapy Combined QL1706, TAS-102 and Bevacizumab in mCRC

Status: NOT_YET_RECRUITING
Phase: PHASE2

Anti-EGFR Agents in Patients With Right-sided Advanced Colorectal Cancer With Wild-type RAS and AREG/EREG High Status

Status: NOT_YET_RECRUITING
Phase: PHASE4

Study of ZG005 in Combination With Gecacitinib in Participants With Advanced Cervical Cancer

Status: RECRUITING
Phase: PHASE1/PHASE2

A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment BNT327 and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer

Status: RECRUITING
Phase: PHASE1/PHASE2

BETWEEN: Biweekly Bevacizumab + Trifluridine/Tipiracil to Reduce Grade 3-4 Neutropenia in mCRC Patients

Status: NOT_YET_RECRUITING
Phase: PHASE2

RC48 Plus Bevacizumab or Pyrotinib in HER2-Positive Metastatic Breast Cancer After T-DXd Failure: A Phase II Study

Status: RECRUITING
Phase: PHASE2